Capricor Therapeutics Inc (OTCMKTS:CAPR) shares saw unusually-strong trading volume on Monday . Approximately 741,300 shares traded hands during mid-day trading, a decline of 27% from the previous session’s volume of 1,021,555 shares.The stock last traded at $2.47 and had previously closed at $2.21.
CAPR has been the subject of several recent research reports. HC Wainwright set a $2.00 target price on shares of Capricor Therapeutics and gave the company a “buy” rating in a research note on Monday, August 14th. ValuEngine raised shares of Capricor Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Monday, October 2nd. Zacks Investment Research raised shares of Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research note on Wednesday, August 16th. Finally, Rodman & Renshaw reissued a “buy” rating and set a $2.15 target price on shares of Capricor Therapeutics in a research note on Saturday, July 22nd.
Capricor Therapeutics (OTCMKTS:CAPR) last released its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.07. The business had revenue of $0.31 million for the quarter, compared to analyst estimates of $1.00 million. During the same period in the prior year, the company earned ($0.29) earnings per share. The firm’s revenue for the quarter was down 58.7% on a year-over-year basis.
Large investors have recently modified their holdings of the stock. LLBH Private Wealth Management LLC lifted its position in shares of Capricor Therapeutics by 27.7% in the 2nd quarter. LLBH Private Wealth Management LLC now owns 184,591 shares of the biotechnology company’s stock valued at $153,000 after acquiring an additional 40,000 shares in the last quarter. Virtu KCG Holdings LLC lifted its position in shares of Capricor Therapeutics by 571.9% in the 2nd quarter. Virtu KCG Holdings LLC now owns 179,301 shares of the biotechnology company’s stock valued at $149,000 after acquiring an additional 152,614 shares in the last quarter. Finally, Wells Fargo & Company MN purchased a new stake in shares of Capricor Therapeutics in the 3rd quarter valued at approximately $107,000.
About Capricor Therapeutics
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.
Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.